Form 4: Nuvation Bio CTOO Granted 748,130 Stock Options

Nuvation Bio's Chief Technical Operations Officer, David C. Hanley, was granted 748,130 stock options with an exercise price of $5.91, vesting over four years.

Summary

• David C. Hanley, Chief Technical Operations Officer of Nuvation Bio Inc. (NUVB), was granted 748,130 stock options.
• The options have an exercise price of $5.91 per share.
• The transaction date for the grant was February 27, 2026.
• The options will vest 25% on the one-year anniversary of the grant date (February 27, 2027), with the remaining balance vesting monthly over the subsequent 36 months.
• The options expire on February 26, 2036.
• The grant is subject to Mr. Hanley's continuous service with the company.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting the company's commitment to retaining and incentivizing key leadership through standard equity compensation practices.

Positives

• Grant of a significant number of stock options (748,130) to a key executive, David C. Hanley, aligns his interests with long-term shareholder value.
• The vesting schedule over four years encourages executive retention and sustained performance.

Negatives

• No immediate cash benefit for the executive; the value is contingent on future stock price appreciation above the $5.91 exercise price.

Risks

• The value of the stock options is subject to the future performance of Nuvation Bio Inc.'s stock price. If the stock price does not exceed the exercise price of $5.91, the options may expire worthless.
• Vesting is contingent on continuous service, meaning the executive must remain employed to realize the full benefit.

Future Outlook

This filing primarily reports a past transaction (grant of options) with future vesting conditions. It implies a long-term commitment from the executive, as the full benefit of the options is realized over a four-year vesting period, contingent on continuous service.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like a Chief Technical Operations Officer is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure aims to incentivize long-term performance and align executive interests with shareholder value, particularly in sectors where innovation and long-term development cycles are critical.

Comparison to Industry Standards

• The grant of 748,130 options to a CTOO is a substantial equity award, comparable to grants seen in similar-sized biotech firms for senior leadership. For instance, a CTO at a peer company like Mirati Therapeutics (MRTX) or Blueprint Medicines (BPMC) might receive similar-sized grants, often tied to performance milestones or long-term retention.
• A four-year vesting schedule with a one-year cliff is a common industry standard designed to ensure executive retention and commitment.
• The exercise price of $5.91 would typically be the closing price of Nuvation Bio's stock on the grant date, which is standard practice for incentive stock options.

Corporate Governance

Related Party Transactions

• The stock option grant is a form of compensation between Nuvation Bio Inc. and its Chief Technical Operations Officer, David C. Hanley, which is a standard related party transaction disclosed via Form 4.

Stakeholder Impact

• Shareholders: The grant aligns executive interests with shareholder value creation, as the options gain value only if the stock price increases. It also represents potential future dilution if options are exercised.
• Employees: Demonstrates the company's use of equity compensation to incentivize and retain key talent.

Next Steps

• Continued service by David C. Hanley to meet vesting conditions.
• Potential exercise of options by David C. Hanley after vesting, contingent on Nuvation Bio's stock price performance.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for Nuvation Bio Inc. While it signals executive alignment, it's not a catalyst for a 'buy' or 'sell' recommendation on its own. Investors should continue to hold and monitor the company's core business developments and financial performance.

Keywords

Nuvation Bio, NUVB, stock options, executive compensation, Form 4, insider transaction, equity grant, vesting, Chief Technical Operations Officer, David Hanley